Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROSTAT vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Acute relief of angina pectoris,Prophylaxis of angina pectoris before activities that may provoke an attack,Off-label: Treatment of acute heart failure, hypertensive urgency
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
2–3 minutes for initial distribution phase; terminal elimination half-life is approximately 1–4 minutes. Rapid clearance due to extensive metabolism in the liver and other tissues (via glutathione-organic nitrate reductase).
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase and by erythrocytes; CYP450 not primarily involved.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Renal excretion of inactive metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for about 35%. Unchanged nitroglycerin is minimally excreted in urine (<1%).
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Approximately 60% bound to plasma proteins (albumin and possibly others).
~28% bound to albumin.
3–4 L/kg, indicating extensive distribution into tissues, particularly vascular smooth muscle and other highly perfused organs.
2–4 L/kg, indicating extensive tissue distribution.
Sublingual: 30–60% (bypasses first-pass hepatic metabolism). Oral: <10% due to extensive first-pass metabolism. Transdermal: 10–20% depending on formulation and application site. Intravenous: 100%.
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No dosage adjustment required for renal impairment; use with caution in patients with severe renal impairment due to potential for hypotension.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Caution, consider dose reduction; Child-Pugh Class C: Avoid use due to increased risk of methemoglobinemia.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Not recommended for use in children due to lack of safety and efficacy data.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Initiate at lower end of dosing range (0.3 mg) due to increased sensitivity to vasodilation and higher risk of hypotension; monitor closely.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) as this can cause severe hypotension, syncope, or myocardial ischemia.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension and reflex tachycardia may occur,May exacerbate angina due to excessive hypotension,Tolerance may develop with prolonged use,Abrupt discontinuation may precipitate angina
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to nitroglycerin,Concurrent use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe hypotension (systolic BP <90 mm Hg),Cardiac tamponade, constrictive pericarditis, or restrictive cardiomyopathy,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage)
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Avoid alcohol, which can enhance hypotensive effects and cause severe dizziness or fainting. Grapefruit juice may increase nitroglycerin absorption and risk of adverse effects. No other significant food interactions.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: risk of fetal bradycardia and hypotension. Avoid near term due to potential for maternal hypotension and reduced uterine blood flow.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio unknown. No known adverse effects in infants. Use with caution, especially in nursing of premature or ill infants.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No specific dose adjustment required for pregnancy; however, due to increased plasma volume and altered hemodynamics, monitor efficacy and titrate to response. Use lowest effective dose to minimize maternal hypotension.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Nitroglycerin sublingual tablets (Nitrostat) are first-line for acute angina. Store in original glass bottle, tightly closed; potency degrades with exposure to light, heat, and moisture. Patients should feel a tingling or burning sensation under the tongue—if absent, tablet may be ineffective. Administer 0.3-0.6 mg at first sign of angina; may repeat every 5 minutes up to 3 doses. If pain persists after 3 doses, seek emergency care. Contraindicated with recent use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Hypotension and reflex tachycardia are common; monitor blood pressure. Tolerance develops with sustained use; use minimal effective dose and allow nitrate-free interval (10-12 hours daily) for long-acting forms.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Take at the first sign of chest pain; do not wait for severe pain.,Place the tablet under the tongue or between the cheek and gum; do not swallow or chew.,Sit or lie down when taking to avoid dizziness or fainting from low blood pressure.,If no relief after 5 minutes, repeat one dose; if still no relief after 3 doses in 15 minutes, call 911 immediately.,Store in the original glass bottle, tightly closed, away from heat and light; do not store in bathroom or kitchen.,Replace the bottle 6 months after opening, as the medication loses potency.,Do not drink alcohol while taking this medication; it can cause severe hypotension.,Do not take with erectile dysfunction drugs (Viagra, Cialis, Levitra) as it can cause a fatal drop in blood pressure.,Avoid grapefruit juice as it may increase side effects.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROSTAT vs ISORDIL, answered by our medical review team.
NITROSTAT is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROSTAT and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROSTAT is: 0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROSTAT and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROSTAT is classified as Category C. FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: ris. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.